| SCHEDULE OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY |
A
roll-forward of activity is presented below for the year ended March 31, 2025:
SCHEDULE
OF SERIES B PREFERRED STOCK FOR MEZZANINE EQUITY
| | |
2025 | | |
2024 | |
| | |
$ | | |
$ | |
| Balance beginning of year – March 31 | |
| 1,488,920 | | |
| — | |
| Net proceeds received pursuant to the issuance of preferred shares | |
| 1,732,532 | | |
| 2,825,000 | |
| Recognition of derivative liabilities (Note 8) | |
| (649,533 | ) | |
| (964,446 | ) |
| Conversion into common shares | |
| (571,629 | ) | |
| (371,634 | ) |
| Balance end of year – March 31 | |
| 2,000,290 | | |
| 1,488,920 | |
|
| SCHEDULE OF WARRANTS OUTSTANDING |
Warrant
activity during the years ended March 31, 2025 and 2024 is indicated below:
SCHEDULE
OF WARRANTS OUTSTANDING
| | |
Broker Warrants | | |
Consultant and Noteholder Warrants | | |
Warrants Issued on Convertible Notes | | |
Total | |
| As at March 31, 2023 | |
| 139,865 | | |
| 279,341 | | |
| 888,277 | | |
| 1,307,483 | |
| Expired/cancelled | |
| — | | |
| (25,347 | ) | |
| (888,277 | ) | |
| (913,624 | ) |
| Issued | |
| 69,062 | | |
| — | | |
| 868,098 | | |
| 937,160 | |
| As at March 31, 2024 | |
| 208,927 | | |
| 253,994 | | |
| 868,098 | | |
| 1,331,019 | |
| Beginning balance | |
| 208,927 | | |
| 253,994 | | |
| 868,098 | | |
| 1,331,019 | |
| | |
| | | |
| | | |
| | | |
| | |
| Expired/cancelled | |
| — | | |
| (15,000 | ) | |
| — | | |
| (15,000 | ) |
| Issued | |
| 600,000 | | |
| 1,200,000 | | |
| — | | |
| 1,800,000 | |
| As at March 31, 2025 | |
| 808,927 | | |
| 1,438,994 | | |
| 868,098 | | |
| 3,116,019 | |
| Ending balance | |
| 808,927 | | |
| 1,438,994 | | |
| 868,098 | | |
| 3,116,019 | |
| | |
| | | |
| | | |
| | | |
| | |
| Exercise Price | |
| $ 0.5 to $22.5 | | |
| $ 0.43 to $14.40 | | |
$ | 4.18 | | |
| | |
| Expiration Date | |
| August 2026 to October 2033 | | |
| March 2029 to Feb 2035 | | |
| October 2027 | | |
| | |
|
| SCHEDULE OF STOCK OPTION ACTIVITIES |
The
following table summarizes the stock option activities during the fiscal year ended March 31, 2025:
SCHEDULE
OF STOCK OPTION ACTIVITIES
| | |
Number of Options | | |
Weighted Average Exercise Price | | |
Weighted Average Remaining Contractual Term (years) | | |
Aggregate Intrinsic Value(1) | |
| | |
| | |
| | |
| | |
| |
| Outstanding at March 31, 2024 | |
| 1,239,873 | | |
$ | 9.39 | | |
| 5.35 | | |
$ | 9,705,937 | |
| Adjustment for rounding effect of Reverse Split | |
| - | | |
| - | | |
| - | | |
| - | |
| Granted | |
| 2,836,176 | | |
$ | 0.5 | | |
| 0.02 | | |
| - | |
| Cancelled | |
| (931,000 | ) | |
| 9.32 | | |
| 4.24 | | |
| - | |
| Expired | |
| (57,582 | ) | |
$ | 0.56 | | |
| 0.17 | | |
| - | |
| Forfeited | |
| (19,637 | ) | |
$ | 0.37 | | |
| 2.34 | | |
| - | |
| Outstanding at March 31, 2025 | |
| 3,067,830 | | |
$ | 1.14 | | |
| 1.77 | | |
$ | 1,078,756 | |
| Vested and expected to vest at March 31, 2025* | |
| 3,067,830 | | |
$ | 1.14 | | |
| 1.77 | | |
$ | 1,078,756 | |
| Vested and exercisable at March 31, 2025* | |
| 2,611,411 | | |
$ | 1.17 | | |
| 0.43 | | |
$ | 805,181 | |
| (1) |
The aggregate intrinsic
value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock
as of March 31, 2025 and fair value of common stock adjusted. |
| * |
This includes 1,200,000 options granted to employees from the 2023 Equity
Incentive Plan, discussed below. |
BIOTRICITY INC.
Notes to Consolidated Financial
Statements
Years ended March 31, 2025
and 2024
(Expressed in US Dollars)
The
following table summarizes the stock option activities during the fiscal year ended March 31, 2024:
| | |
Number of Options | | |
Weighted Average Exercise Price | | |
Weighted Average Remaining Contractual Term (years) | | |
Aggregate Intrinsic Value(1) | |
| | |
| | |
| | |
| | |
| |
| Outstanding at March 31, 2023 | |
| 1,264,890 | | |
$ | 9.29 | | |
| 6.30 | | |
$ | 8,185,321 | |
| Adjustment for rounding effect of Reverse Split | |
| 12,655 | | |
| - | | |
| - | | |
| - | |
| Granted | |
| 7,210 | | |
$ | 2.77 | | |
| 9.01 | | |
| - | |
| | |
| | | |
| | | |
| | | |
| | |
| Expired | |
| (39,520 | ) | |
$ | 3.89 | | |
| 3.76 | | |
| - | |
| Forfeited | |
| (5,362 | ) | |
$ | 12.30 | | |
| 8.85 | | |
| - | |
| Outstanding at March 31, 2024 | |
| 1,239,873 | | |
$ | 9.39 | | |
| 5.35 | | |
$ | 9,705,937 | |
| Vested and expected to vest at March 31, 2024 | |
| 1,239,873 | | |
$ | 9.32 | | |
| 5.35 | | |
$ | 9,806,024 | |
| Vested and exercisable at March 31, 2024 | |
| 1,134,642 | | |
$ | 9.62 | | |
| 5.10 | | |
$ | 9,320,582 | |
| (1) |
The aggregate intrinsic
value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock
as of March 31, 2024 and fair value of common stock adjusted for the Reverse Split as of March 31, 2023 of $1.48 and $2.81 per share,
respectively. |
|